Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_775_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
46 Мб
Скачать
40 Pancreaticoduodenectomy withHepatic Artery Resection
317
either HA reconstruction or PV reconstruction could be per­formed prior to the extraction of the specimen whenever pos­sible. At this time point, it is important to complete the dissection of the pancreas, relevant organs, lymph nodes, and peripancreatic nerve plexus, except for the HAs and PV/ SMV.Cattell-Braasch Maneuver and the resection of porto­mesenterico- splenic conuence could also be used to achieve tension-free anastomosis [30, 31].

40.4.4 Management after HA Reconstruction

Doppler ultrasonography and blood tests need to be routinely performed within the rst 3 postoperative days to detect pos­sible thrombotic complications promptly. If there are any signs or concerns of liver problem, MDCT is immediately performed. Antiplatelet or anticoagulation therapy has rarely been used.

40.5 Conclusions

The recommendations for HA reconstruction were pre­sented. Detailed preoperative image preparation, planning of several options of HA reconstruction, precise intraoperative resection, and postoperative Doppler ultrasonography are necessary. Although there are promising reports from limited centers, the technique of PD with HA resection and recon­struction requires higher expertise [5, 7, 9, 18]. With the advancement of chemotherapy and the increase in the num­ber of PC patients, HA reconstruction will be required in many cases in the near future. It is important to accumulate experience, share observations, and improve the techniques through international and multicenter collaborations.
Declaration of Interests Dr. Del Chiaro has received grants from Haemonetics, Inc., and is the principal investigator of the study spon­sored by Boston Scientic, which is not directly associated with the submitted work. The remaining authors have declared no competing interests.

References

1. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(8):1028–61.
2. NCCN clinical practice guidelines in oncology: pancreatic adeno­carcinoma, version 1.2020. 2020.
3. Fortner JG, Kim DK, Cubilla A, Turnbull A, Pahnke LD, Shils ME.Regional pancreatectomy: en bloc pancreatic, portal vein and lymph node resection. Ann Surg. 1977;186(1):42–50.
4. Oba A, Bao QR, Barnett CC, Al-Musawi MH, Croce C, Schulick RD, etal. Vascular resections for pancreatic ductal adenocarcinoma: vascular resections for PDAC.Scand J Surg. 2020;109(1):18–28.
5. Loos M, Kester T, Klaiber U, Mihaljevic AL, Mehrabi A, Muller­Stich BM, et al. Arterial resection in pancreatic cancer surgery: effective after a learning curve. Ann Surg. 2020; https://doi.
org/10.1097/SLA.0000000000004054.
6. Westermark S, Rangelova E, Ansorge C, Lundell L, Segersvard R, Del Chiaro M.Cattell-Braasch maneuver combined with local hypothermia during superior mesenteric artery resection in pancre­atectomy. Langenbeck’s Arch Surg. 2016;401(8):1241–7.
7. Truty MJ, Colglazier JJ, Mendes BC, Nagorney DM, Bower TC, Smoot RL, etal. En bloc celiac axis resection for pancreatic cancer: classication of anatomical variants based on tumor extent. J Am Coll Surg. 2020;231(1):8–29.
8. Sato T, Inoue Y, Takahashi Y, Mise Y, Ishizawa T, Tanakura K, etal. Distal pancreatectomy with celiac Axis resection combined with reconstruction of the left gastric artery. J Gastrointest Surg. 2017;21(5):910–7.
9. Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P.Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes?: a single Institution’s expe­rience with 118 patients. Ann Surg. 2020;271(5):932–40.
10. Oba A, Croce C, Hosokawa P, Meguid C, Torphy RJ, Al-Musawi MH, et al. Prognosis based denition of resectability in pan­creatic cancer: a road map to new guidelines. Ann Surg. 2022;275(1):175–81.
11. Oba A, Wu YA, Schulick RD, Del Chiaro M. Pancreatic surgery with arterial resections. Textbook of pancreatic cancer. Springer;
2021. p.877–89.
12. Inoue Y, Saiura A, Oba A, Ono Y, Mise Y, Ito H, etal. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery. J Hepatobiliary Pancreat Sci. 2021;28(2):143–55.
13. Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, etal. Surgery improves survival after neoadjuvant therapy for bor­derline and locally advanced pancreatic cancer: a single institution experience. Ann Surg. 2021;273(3):579–86.
14. Oba A, Inoue Y, Ono Y, Irie S, Sato T, Mise Y, etal. Radiologically occult metastatic pancreatic cancer: how can we avoid unbenecial resection? Langenbeck’s Arch Surg. 2020;405(1):35–41.
15. Oba A, Inoue Y, Ono Y, Ishizuka N, Arakaki M, Sato T, et al. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and uorescence imaging: the SLING trial. Br J Surg. 2021;108(2):115–8.
16. Ushida Y, Inoue Y, Ito H, Oba A, Mise Y, Ono Y, etal. High CA19-9 level in resectable pancreatic cancer is a potential indication of neo­adjuvant treatment. Pancreatology. 2021;21(1):130–7.
17. Sato T, Saiura A, Inoue Y, Takahashi Y, Arita J, Takemura N.Distal pancreatectomy with en bloc resection of the celiac axis with pres­ervation or reconstruction of the left gastric artery in patients with pancreatic body cancer. World J Surg. 2016;40(9):2245–53.
18. Otsuka S, Kaneoka Y, Maeda A, Takayama Y, Fukami Y, Onoe S.Hepatic artery reconstruction with a continuous suture method for hepato-biliary-pancreatic surgery. World J Surg. 2016;40(4):951–7.
19. Hackert T, Weitz J, Büchler MW. Splenic artery use for arterial reconstruction in pancreatic surgery. Langenbeck’s Arch Surg. 2014;399(5):667–71.
20. Kinny-Koster B, van Oosten F, Habib JR, Javed AA, Cameron JL, Lafaro KJ, etal. Mesoportal bypass, interposition graft, and mesoca­val shunt: surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Surgery. 2020;168(6):1048–55.
21. Ito H, Takahashi Y, Saiura A.Commentary: complex venous resec­tion and reconstruction for locally advanced pancreatic cancer: our approach. Surgery. 2020;168(6):1056–7.
22. Inoue Y, Saiura A, Yoshioka R, Ono Y, Takahashi M, Arita J, etal. Pancreatoduodenectomy with systematic mesopancreas dissec­tion using a supracolic anterior artery-rst approach. Ann Surg. 2015;262(6):1092–101.
318
A. Oba et al.
23. Del Chiaro M, Segersvärd R, Rangelova E, Coppola A, Scandavini CM, Ansorge C, etal. Cattell-Braasch Maneuver combined with artery-rst approach for superior mesenteric-portal vein resection during pancreatectomy. J Gastrointest Surg. 2015;19(12):2264–8.
24. Sanjay P, Takaori K, Govil S, Shrikhande S, Windsor J. ‘Artery­rst’ approaches to pancreatoduodenectomy. Br J Surg. 2012;99(8):1027–35.
25. Inoue Y, Saiura A, Takahashi Y. A novel classication and staged approach for dissection along the celiac and hepatic artery during pancreaticoduodenectomy. World J Surg. 2018;42(9):2963–7.
26. Del Chiaro M, Schulick RD.Commentary on: divestment or skel­etonization of the SMA or the hepatic artery for locally advanced pancreatic ductal cancer after neoadjuvant therapy. Surgery. 2021;169(5):1039–40.
27. Del Chiaro M, Schulick RD.Use of total pancreatectomy and pre­operative radiotherapy in patients undergoing pancreatectomy with artery resection. J Am Coll Surg. 2019;228(1):131.
28. Stoop TF, Ateeb Z, Ghorbani P, Scholten L, Arnelo U, Besselink MG, etal. Surgical outcomes after total pancreatectomy: a high­volume center experience. Ann Surg Oncol. 2021;28(3):1543–51.
29. Oba A, Inoue Y, Sato T, Ono Y, Mise Y, Ito H, etal. Impact of indo­cyanine green-uorescence imaging on distal pancreatectomy with celiac axis resection combined with reconstruction of the left gas­tric artery. HPB. 2019;21(5):619–25.
30. Del Chiaro M, Segersvard R, Rangelova E, Coppola A, Scandavini CM, Ansorge C, et al. Cattell-Braasch Maneuver combined with artery-rst approach for superior mesenteric­portal vein resection during pancreatectomy. J Gastrointest Surg. 2015;19(12):2264–8.
31. Oba A, Ito H, Ono Y, Sato T, Mise Y, Inoue Y, etal. Regional pan­creatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. BJS open. 2020;4(3):438–48.
Pancreaticoduodenectomy withSplenic Artery Resection forTumors ofthePancreatic Head and/or Body Invading theSplenic Artery
ShugoMizuno, KazuyukiGyoten, andMotonoriNagata
41
Abstract
Background: We have developed a new surgical tech­nique, pancreaticoduodenectomy (PD) with splenic artery (SA) resection (PD-SAR), for tumors of the pancreatic head and/or body with SA invasion. In PD with portal vein (PV)/superior mesenteric vein (SMV) conuence resection, splenic vein (SV) division may cause left-sided portal hypertension (LPH).
Methods: Ninety-ve patients with pancreatic ductal adenocarcinoma who underwent PD with PV/SMV resec­tion after chemoradiotherapy were classied into three groups: PD-SVP (SV and SA were preserved, n= 23), PD-SVR (SV was divided and SA was preserved, n=55), and PD-SAR (SV and SA were divided, n=17). We eval­uated the inuence of SV and/or SA resection on LPH after PD with PV/SMV resection.
Results: Postoperative computed tomography demon­strated remnant pancreas enhancement in all patients in PD-SAR.The incidence of postoperative variceal forma­tion in PD-SVP, PD-SVR, and PD-SAR was 4.3%, 60.9%, and 41.2%, respectively (p<0.001), and variceal bleed­ing occurred only in PD-SVR (n=4, 7.3%). The platelet counts (×10 138, and 154in PD-SVP, PD-SVR, and PD-SAR, respec­tively (PD-SVP vs. PD-SVR, p<0.001), and spleen vol­ume (mL) at 6months was 91.8, 160, and 115in PD-SVP, PD-SVR, and PD-SAR, respectively (PD-SVP vs. PD-SVR, p<0.001). No signicant differences in overall survival were observed among all groups.
S. Mizuno (*) · K. Gyoten Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Tsu, Mie, Japan e-mail: mizunos@clin.medic.mie-u.ac.jp
M. Nagata Department of Radiology, Mie University Graduate School of Medicine, Tsu, Mie, Japan
3
/μL) at postoperative 6 months were 185,
Conclusion: In PD with PV-SMV conuence resec­tion, SV division causes LPH; however, concomitant divi­sion of the SV and SA may attenuate this risk.

41.1 Introduction

In 2014, we developed and reported a new surgical technique for proximal subtotal pancreatectomy with splenic artery (SA) and splenic vein (SV) resection, so-called pancreatico­duodenectomy (PD) with SA resection (PD-SAR), for tumors of the pancreatic head and/or body invading the SA [1]. Although insufcient blood ow to the remnant pancreas was a concern, we have not experienced any postoperative complications related to lack of blood supply to the pancre­atic parenchyma in patients who underwent PD-SAR. In addition, we have revealed that PD-SAR could achieve cura­tive resection of tumors and prevent total pancreatectomy, which inevitably leads to diabetes mellitus and poor quality of life.
In cases of PD with combined resection of the portal vein
(PV)/superior mesenteric vein (SMV) conuence, left-sided portal hypertension (LPH) resulting in variceal bleeding and thrombocytopenia due to hypersplenism has been a focus of recent studies [24]. In patients undergoing PD-SAR, the tumors frequently involve the PV and/or SMV or the PV-SMV conuence, and patients need to undergo combined resection of the PV/SMV and/or SV, with a risk of LPH development.
With respect to the splenic circulation, it has been consid-
ered that PD with SA resection could reduce the portal venous pressure because SA embolization/ligation or sple­nectomy is proven to reduce portal hyperperfusion, resulting in improvement of small-for-size syndrome in living-donor liver transplant patients [5]. PD-SAR is expected to reduce the portal venous pressure, resulting in improvement of LPH after PD.
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022 M. Makuuchi et al. (eds.), The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases,
https://doi.org/10.1007/978-981-19-0063-1_41
319
320
S. Mizuno et al.
The aim of the present study was to introduce the surgical technique of PD-SAR and to evaluate its efcacy by examin­ing the surgical outcomes, prognosis, and incidence of LPH after PD-SAR in comparison with conventional PD, with attention to the development of variceal formation and bleed­ing, as well as postoperative changes in platelet count and spleen volume.
41.2 Surgical Procedures ofPD-SAR
The conventional PD for pancreatic ductal adenocarcinoma (PDAC) has been standardized as an anterior approach to the superior mesenteric artery at our institution [6, 7]. When the tumor is invading the PV/SMV, we perform resection and reconstruction of the PV and SMV using 6-0 nonabsorbable running sutures. In cases of tumors involving the SV or infe­rior mesenteric vein (IMV), these veins are divided and not reconstructed. When tumor involvement of the SA is identi­ed, PD-SAR is employed [1]. Pancreaticojejunostomy is performed using the pair-watch suturing technique, as described in our previous report [8].
The surgical procedures of PD-SAR are similar to those of PD, except for combined resection of the SA and SV (Fig.41.1a, b). Focusing on the arterial anatomy around the pancreas and the cutting sites of the artery, the blood supply of the remnant pancreas is provided by the short gastric arter­ies, left gastroepiploic artery, and posterior epiploic artery [9]. During surgery, sufcient blood supply of the remnant pancreas and spleen is conrmed with Doppler ultrasonogra­phy and/or by the color of the remnant pancreas and the
spleen. When the tumor is invading both the left gastric artery (LGA) and the SA, we perform combined resection of the LGA followed by total gastrectomy and splenectomy if curative-intent resection is possible. In such cases, the blood supply of the remnant pancreas is provided by posterior epi­ploic artery alone [1].
41.3 Patients andMethods

41.3.1 Patients

Between April 2005 and July 2017, a total of 361 patients who had a cytological or histological diagnosis of localized PDAC, determined using 64-slice multidetector computed tomography (MDCT), underwent our chemoradiotherapy (CRT) protocol, as previously reported [1012] (Fig.41.2). We retrospectively reviewed the electronic medical records of 172 patients who underwent PD after CRT.Among them, 158 (91.8%) patients underwent combined resection of the PV and SMV.The present study nally included 95 patients after excluding 63 patients for the following reasons: con­comitant splenectomy (n=4), postoperative PV/SMV anas­tomotic stricture (n = 8), preoperative portal hypertension (n=7), PV-SV anastomosis (n=1), insufcient follow-up (n=6), death within 30days after the surgery (n=1), con­comitant colectomy (n=7), and SA ligation (n=29). These 95 patients were classied into three groups: PD-SVP (both SV and SA were preserved, n = 23), PD-SVR (SV was divided and SA was preserved, n=55), and PD-SAR (both SV and SA were divided, n=17).
a b
GDA
PV
Fig. 41.1 (a) Intraoperative ndings after pancreaticoduodenectomy
with SA resection (PD-SAR). (b) Schema of reconstruction after PD-SAR. PV portal vein, SMA superior mesenteric artery, SA splenic
CHA
SMV
thecut endof the SA
Rem P
SMA
SA
CHA
SP
GDA
PV
SMA
artery, CHA common hepatic artery, GDA gastroduodenal artery, SV splenic vein, Rem P remnant pancreatic parenchyma, SP spleen
SV
Rem P
41 Pancreaticoduodenectomy with Splenic Artery Resection for Tumors of the Pancreatic Head and/or Body Invading the Splenic…
PDAC (n=361)
(CRT: 2005.3-2017.7)
Exclusion n=21
• Rejection of CRT n=14
• Op at other hospital n=3
• Moved to other hospital n=4
PDAC (n=340)
No pancreatectomy (n=128)
Pancreatectomy (n=212)
321
PD (n=172)
PD without PV/SMV resection (n=14)
PD with PV/SMV resection (n=158)
SA
SV
SV
PD -SVP (n= 23)
SA
PD -SVR (n= 55)
Fig. 41.2 Flow diagram of the enrollment of 361 patients who under-
went PD with combined PV/SMV resection for PDAC after CRT. Between March 2005 and December 2018, 158 patients with PDAC underwent PD with PV resection after CRT.After excluding 63 patients, the present study enrolled 95 patients: PD-SVP (n = 23),

41.3.2 Preoperative Treatments

Our treatment protocols for gemcitabine-based chemother­apy (G-CRT) and gemcitabine plus gemcitabine-based CRT (GS-CRT) have been reported previously [11, 13]. Between February 2005 and October 2011, patients were adminis­tered an infusion of gemcitabine at a dose of 800mg/m days 1, 8, 22, and 29 for one cycle (G-CRT). From November 2011, patients were administered S1 orally twice daily at a
2
dose of 60 mg/m
per day on days 1 through 21 of a 28-day cycle, and an infusion of gemcitabine at a dose of 600 mg/m2 on days 8 and 22 for one cycle (GS-CRT). Patients were treated with three-dimensional conformal radiotherapy using the four-eld box technique from direc­tions that avoided exposure of the kidney, which is an organ at risk. The total radiation dose delivered was 45–50.4Gy in 25–28 fractions (5 fractions/week). The patients underwent reassessment at 4–6weeks after CRT.When we determined that curative-intent resection was possible, the patients were scheduled to undergo pancreatectomy.
2
on
DP (n=39) TP (n=1)
Exclusion n = 63
• Splenectomy 4
• Postoperative PV/SMV anastomotic stricture 8
• Preoperative portal hypertension 7
• PV-SV anastomosis 1
• Insufficient follow-up 6
• Death within 30 days after operation 1
• Concomitant colectomy 7
• Splenic artery ligation 29
SA
SV
PD -SAR (n= 17)
PD-SVR (n=55), and PD-SAR (n=17). PDAC pancreatic ductal ade­nocarcinoma, CRT chemoradiotherapy, PD pancreaticoduodenectomy,
DP distal pancreatectomy, TP total pancreatectomy, PV portal vein, SMV superior mesenteric vein, SV splenic vein, SVP splenic vein pres- ervation, SAR splenic artery resection, SVR splenic vein resection
41.3.3 Preoperative Characteristics andSurgical Outcomes
We compared various variables among the three groups, including preoperative characteristics such as age, sex, body mass index, maximum tumor size on computed tomography (CT), performance status, tumor marker (car­cinoembryonic antigen and carbohydrate antigen 19-9) lev­els, presence of preoperative CRT including regimens, T and N factors according to the Union for International Cancer Control eighth classication, and tumor resectabil­ity (classied as resectable, borderline resectable, and unresectable according to the National Comprehensive Cancer Network guideline) [14] based on the ndings of MDCT, as previously reported. We also collected data on surgical outcomes, including intraoperative blood loss, operative duration, degree of postoperative complications according to the Clavien-Dindo classication [15], and pancreatic stula according to the International Study Group on Pancreatic Fistula [16].
322
S. Mizuno et al.
41.3.4 Assessment ofLPH: Incidence ofVariceal Formation, Serial Changes ofPlatelet Count, Spleen Volume, andHemodynamics intheLeft-SideArea
To assess the development of LPH, a radiologist (N.M.) who was blinded to the patients’ characteristics and outcomes evaluated enhanced MDCT images for any newly developed varices and collateral pathways at 6 months after PD. Esophageal, gastric, pancreatic, and colonic varices were diagnosed when dilated and beaded veins were detected within the submucosal layer of each organ compared with before the surgery. Collateral pathways from the divided SV were diagnosed when the diameter of the splenosystemic or splenoportal routes was 1.5 times larger than that before sur­gery. The splenosystemic route was dened as a splenorenal shunt, a gastrorenal shunt, and others. Splenoportal routes were classied as superior and inferior routes according to the denition of Strasberg etal. [17]. The superior route was dened as a pathway starting in the divided SV; following a superior and rightward direction through gastric, coronary, and/or perigastric veins; and nally ending in the PV. The inferior route was dened as a pathway starting in the divided SV, joining the venous routes in the mesocolon through the gastrocolic ligament and/or the IMV, and proceeding in an inferior and rightward direction to end in the SMV. Blood supply to the spleen after PD-SAR was evaluated using enhanced MDCT within 10 days postoperatively. Platelet count data were collected before and 6months after PD.The total spleen volume was estimated by tracing the spleen on each transverse CT image obtained at 2.0-mm intervals. Spleen volume was measured before and 6 months after PD. We withdrew the evaluation of LPH when PV/SMV occlusion or patient mortality occurred. The study protocol was approved by the Medical Ethics Committee of Mie University Hospital (no. H2019–070), and the study was performed in accordance with the ethical standards estab­lished in the 1964 Declaration of Helsinki.

41.4 Results

41.4.1 Patients’ Background andSurgical Outcomes
Table 41.1 shows a comparison of background characteris­tics and surgical outcomes between PD-SVP, PD-SVR, and PD-SAR. The intraoperative blood loss was signicantly higher in PD-SVR than in PD-SVP and PD-SAR (464 vs. 1160 vs. 578mL, p=0.004). The incidence rates of coronary vein division and IMV division were as follows (PD-SVP vs. PD-SVR vs. PD-SAR): 60.9% vs. 89.1% vs. 82.4% (p = 0.015) and 13.0% vs. 60.0% vs. 94.1% (p <0.001), respectively. No signicant differences were observed in postoperative complications of Clavien-Dindo grade IIIa or higher and in pancreatic stula of grade B or C between the two groups. The incidence rates of pathological PV invasion were 8.7% in PD-SVP, 25.5% in PD-SVR, and 47.1% in PD-SAR (p= 0.022). The incidence rates of postoperative variceal formation and splenosystemic shunt development were as follows (PD-SVP vs. PD-SVR vs. PD-SAR): 4.3% vs. 70.9% vs. 41.2% (p < 0.001) and 4.3% vs. 45.5% vs.
5.9% (p<0.001), respectively. Variceal bleeding was identi-
ed in four patients (7.3%), all in PD-SVR (p=0.212).
41.4.2 Arterial Blood Supply totheLeft-Sided Area after PD-SAR
Blood supply to the spleen after PD-SAR (n = 17) was secured from the LGA and subphrenic artery (SubPA), which passed through the stomach and joined to the distal SA and spleen. On dynamic CT imaging performed within 10days after PD-SAR, blood supply from the LGA and SubPA was identied in 100% (17/17) and 94.1% (16/17), respectively. PD-SAR did not cause any severe complications, such as spleen necrosis and abscess. Partial splenic infarction was identied in 11.8% (2/17) of the patients, although all of them improved within 1month.

41.3.5 Statistical Analyses

Continuous variables are expressed as medians and ranges. Statistical signicance was determined using the Mann­Whitney U test for comparison between two groups and the Kruskal–Wallis test for comparison among multiple groups. Categorical variables were compared using Pearson’s chi­square test. Overall survival (OS) was calculated using the Kaplan-Meier method and tested using the log-rank test. Statistical analysis was performed using SPSS version 24.0 (SPSS, Chicago, IL, USA). A p value of <0.05 was consid­ered statistically signicant.
41.4.3 Serial Changes ofPlatelet Count andSpleen Volume
Figure 41.3a shows the change in platelet counts. At postop­erative 6months, the median platelet count (×103/μL) in the PD-SVR group was signicantly lower than that in the PD-SVP group (138 vs. 185, p< 0.001). The postoperative platelet counts (×103/μL) signicantly decreased compared with the preoperative counts only in PD-SVR (138 vs. 205, p<0.001). Figure41.3b shows the change in spleen volume. At 6months postoperatively, the median spleen volume in PD-SVR was signicantly larger than that in PD-SVP (160
41 Pancreaticoduodenectomy with Splenic Artery Resection for Tumors of the Pancreatic Head and/or Body Invading the Splenic…
Table 41.1 Background and surgical outcomes
Perioperative variables PD-SVP n=23 PD-SVR n=55 PD-SAR n=17 p Age 68 (52~84) 66 (48~84) 69 (53~82) 0.344 Man/female 10/13 39/16 8/9 0.038 BMI, kg/m Maximum tumor size on CT (mm) 25.3 (13.1~38.7) 25.7 (11.2~45.9) 25.4 (12.3~72.6) 0.894 Performance status 0/1/2 15/6/2 31/23/1 13/4/0 0.208 CEA, ng/mL 3.4 (1.0~8.4) 4.2 (1.0~13.2) 2.8 (1.4~369) 0.166 CA19-9, U/mL 28.9 (0.1~497) 34.2 (0.1–1690) 43.1 (0.1–1475) 0.981 TNM classication (UICC 8th) T factor (T1/T2/T3/T4) 4/8/0/11 10/19/3/23 1/3/0/13 0.244 TNM classication (UICC 8th) N factor (N0/N1/N2) 17/6/0 41/13/1 14/3/0 0.885 Resectability, R: BR: UR 10/7/6 20/20/15 1/9/7 0.128 Preoperative chemotherapy regimen
G: GS Platelet counts, ×1000/uL 214 (150~447) 205 (87.0~423) 190 (83.0~298) 0.088 Spleen volume, mL 121 (43.2~416) 118 (28.8~277) 104 (57.9~223) 0.850 Operative procedures (PD/SSPPD) 0/23 6/51 3/42 0.246 Operative duration (min) 533 (345~818) 552 (351~780) 604 (384–804) 0.680
Blood loss (mL) 464 (103~2500) 1160 (110~5089) 578 (80~4000) 0.004 CV division, yes/no (%) 14/9 (60.9%) 49/6 (89.1%) 14/3 (82.4%) 0.015 IMV division, yes/no (%) 3/20 (13.0%) 33/22 (60.0%) 16/1 (94.1%) <0.001
C-D >/= IIIa, yes/no (yes %) 2/21 (8.7%) 15/40 (27.3%) 2/15 (11.8%) 0.112 Pancreatic stula (Grade B or C), yes/no (yes %) 0/23 3/52 (5.5%) 0/17 0.324
pPV positive, yes/no (yes%) 2/21 (8.7%) 14/41 (25.5%) 8/9 (47.1%) 0.022
R0 resection, yes/no (yes %) 21/2 (91.3%) 50/5 (90.9%) 12/5 (70.6%) 0.071 Postoperative chemotherapy, yes/no (yes %) 23/0 (100%) 45/10 (81.8%) 13/4 (76.5%) 0.056
Postoperative variceal formation, yes/no (%) 1/22 (4.3%) 39/16 (70.9%) 7/10 (41.2%) <0.001
Esophageal varices 0/23 (0.0%) 18/37 (32.7%) 3/14 (17.6%) 0.006 Gastric varices 0/23 (0.0%) 19/36 (34.5%) 5/12 (29.4%) 0.005 Pancreatic varices 0/23 (0.0%) 15/40 (27.3%) 2/15 (11.8%) 0.013 Colonic varices 1/22 (4.3%) 25/30 (45.5%) 1/16 (5.9%) <0.001
The development of spleno-systemic shunt, yes/no (yes %) 0/23 11/44 (20.0%) 1/16 (5.9%) 0.035
Spleno-renal shunt 0/23 3/52 (5.5%) 0/17 (0.0%) 0.324 Gastro-renal shunt 0/23 7/48 (12.7%) 1 /16 (5.9%) 0.167 Others 0/23 2/53 (3.6%) 0/17 (0.0%) 0.476 The development of superior collateral route, yes/no (yes %) 0/23 (0.0%) 0/57 (0.0%) 0/45 (0.0%) – The development of inferior collateral route, yes/no (yes %) 3/20 (13.0%) 15/40 (27.3%) 3/14 (17.6%) 0.342 Variceal bleeding, yes/no (%) 0/23 4/51 (7.3%) 0/17 (0.0%) 0.219
2
20.6 (15.2~27.1) 20.6 (15.2~28.3) 21.5 (17.3~25.6) 0.848
7/16 26/29 6 / 11 0.532
323
vs. 91.8mL, p<0.001). In PD-SVR, spleen volume signi­cantly increased compared with that before the surgery (160 vs. 118mL, p<0.001).
41.4.4 OS Rates After theInitial Treatment
A signicant difference in median survival time and OS rates was observed among the three groups (PD-SVP vs. PD-SVR vs. PD-SAR): median survival time, 36 vs. 26 vs. 26months; 3-year OS, 46.5% vs. 32.7% vs. 34.0% (p=0.272).

41.5 Discussion

In this paper, we described the surgical techniques of PD-SAR and revealed the following insights: (1) PD-SAR can be safely performed without any major complications
related to this procedure. (2) PD-SAR decreases variceal for­mations due to LPH after SV division compared with PD-SVR. (3) We have never experienced cases of variceal bleeding caused by LPH in patients who underwent PD-SAR.
To justify the PD-SAR procedure, sustained blood supply to the spleen and remnant pancreas is mandatory. The arterial blood supply to the spleen after PD-SAR was secured from the LGA (100%) and the left SubPA (94.1%) through and around the stomach without causing any major complica­tions. In addition to the arterial blood ow on dynamic CT images within 10 days, MDCT clearly demonstrated enhancement of the remnant pancreas at 1 and 6 months postoperatively in all the examined patients (data not shown). The secondary point is the oncological validity of PD-SAR.With respect to the R0 resection rates, no signi­cant differences were observed among the three groups (PD-SVP, PD-SVR, and PD-SAR) regardless of tumor extension. Additionally, surgical outcomes such as degree of
324
3
before Op 6 months after Opbefore Op 6 months after Op
ab
S. Mizuno et al.
500
400
/uL)
300
200
Platelet counts (x 10
100
0
Fig. 41.3 Changes of platelet counts and spleen volume. (a) At
6 months postoperatively, the median platelet count in the PD-SVR group was signicantly lower than that in the PD-SVP group. Only in PD-SVR, platelet counts signicantly decreased compared with the preoperative counts. (b) Change of spleen volume. At 6months postop-
PD-SVP
PD-SVR
PD-SAR
500
400
300
200
Spleen volume (ml)
100
0
eratively, the median spleen volume in the PD-SVR group was signi­cantly larger than that in the PD-SVP group. Only in PD-SVR, the spleen volume signicantly increased compared with before the sur­gery. ‡ p<0.01, § p<0.001. Op operation
*
23 55
*
17 21 51 16
postoperative complications and pancreatic stula did not differ among the three groups. The OS of the PD-SAR group was very similar to that of the PD-SVP and PD-SVR groups.
Acknowledgments We are grateful to Dr. Takehiro Fujii, Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Mie, Japan, for help in creating the schema.
As previously reported [18], LPH is a clinical syndrome due to outow obstruction of the SV when the SV is ligated and not reimplanted, leading to the development of varices
Disclosure The authors of this manuscript have no conicts
of interest to disclose.
with hemorrhage and splenomegaly with thrombocytopenia. Although rare, LPH-related gastrointestinal bleeding is a life-threatening complication, and it can be managed depend-

References

ing on the situation with endoscopic procedures, radiologic procedures, or surgical intervention, with a low mortality. We experienced four patients who developed variceal bleed­ing and required treatments at 6, 6, 18, and 96months after PD, respectively [19]. All four patients underwent PD-SVR, and LPH did not occur in patients who underwent PD-SAR.
In summary, we have developed a PD-SAR procedure for pancreatic head and body tumors invading the SA without attempting to prevent LPH after PV/SMV conuence resec­tion; however, unexpectedly, this procedure was observed to attenuate the development of LPH.Consequently, SA liga­tion or division may be a useful and simple procedure to pre­vent LPH when PV/SMV conuence resection is performed. Nevertheless, further studies with a large number of cases are required to clarify its efcacy.
1. Desaki R, Mizuno S, Tanemura A, etal. A new surgical technique of pancreaticoduodenectomy with splenic artery resection for duc­tal adenocarcinoma of the pancreatic head and/or body invading splenic artery. Biomed Res Int. 2014;2014:219038.
2. Mizuno S, Kato H, Yamaue H, etal. Left-sided portal hypertension after pan- creaticoduodenectomy with resection of the portal vein/ superior mesenteric vein conuence in patients with pancreatic cancer: a project study by the Japanese Society of Hepato-Biliary­Pancreatic Surgery. Ann Surg. 2021;274(1):e36–44. https://doi.
org/10.1097/sla.0000000000003487.
3. Tanaka H, Nakao A, Oshima K, et al. Splenic vein reconstruction is unnecessary in pancreatoduodenectomy combined with resection of the superior mesen- teric vein-portal vein conuence according to short-term outcomes. HPB (Oxford). 2017;19:785–92.
4. Ono Y, Matsueda K, Koga R, etal. Sinistral portal hypertension after pancreaticoduodenectomy with splenic vein ligation. Br J Surg. 2017;102(3):219–28.
41 Pancreaticoduodenectomy with Splenic Artery Resection for Tumors of the Pancreatic Head and/or Body Invading the Splenic…
325
5. Ikegami T, Shimada M, Imura S, et al. Current concept of small­for- size grafts in living donor liver transplantation. Surg Today. 2008;38:971–82.
6. Isaji S, Usui M, Sakurai H, etal. Antegrade proximal pancreatec­tomy for lower bile duct adenocaricinoma and ampulla of Vater car­cinoma. Operation. 2007;61:821–7. (In Japanese)
7. Mizuno S, Isaji S, Tanemura A, etal. Anterior approach to the supe­rior mesenteric artery by using nerve plexus hanging maneuver for borderline resectable pancreatic head carcinoma. J Gastrointest Surg. 2014;18(6):1209–15.
8. Azumi Y, Isaji S, Kato H, Nobuoka Y, Kuriyama N, Kishiwada M, Hamada T, Mizuno S, Usui M, Sakurai H, Tabata M.A standard­ized technique for safe pancreaticojejunostomy: pair-watch sutur­ing technique. World J Gastrointest Surg. 2010;2:260–4.
9. Mizuno S, Isaji S, Ohsawa I, etal. Pancreaticoduodenectomy with resection of the splenic artery and splenectomy for pancreatic dou­ble cancers after total gastrectomy. Preservation of the pancreatic function via the blood supply from the posterior epiploic artery: report of a case. Surg Today. 2012;42:482–8.
10. Yamada R, Mizuno S, Uchida K, etal. Human equilibrative nucle­oside transporter 1 expression in endoscopic ultrasonography– guided ne-needle aspiration biopsy samples is a strong predictor of clinical response and survival in the patients with pancreatic ductal adenocarcinoma undergoing gemcitabine-based chemora­diotherapy. Pancreas. 2016;45:761–71.
11. Kobayashi M, Mizuno S, Murata Y, et al. Gemcitabine-based chemoradiotherapy followed by surgery for borderline resect­able and locally unresectable pancreatic ductal adenocarcinoma. Pancreas. 2014;43:350–60.
12. Isaji S, Kishiwada M, Kato H. Surgery for borderline pancreatic cancer: the Japanese experience. In: Katz MD, Ahmad SA, edi-
tors. Multimodality management of borderline resectable pancre­atic cancer. Cham: Springer International Publishing Switzerland;
2016. p.265–87.
13. Takeuchi T, Mizuno S, Murata Y, etal. Comparative study between gemcitabine-based and gemcitabine plus S1–based preoperative chemoradiotherapy for localized pancreatic ductal adenocarci­noma, with special attention to initially locally advanced unresect­able T tumor. Pancreas. 2019;48:281–91.
14. National Comprehensive Cancer Network. Pancreaticadenocarcinoma. NCCN clinical practice guidelines in oncology. Version 2. 2016. http://www.nccn.org/professionals/phy-
sician_gls/pdf/pancreatic.pdf. Accessed 14 Jun 2018.
15. Dindo D, Demartines N, Clavien PA. Classication of surgical complications. Ann Surg. 2004;240:205–13.
16. Bassi C, Dervenis C, Butturini G, etal. International Study Group on Pancreatic Fistula Denition. Postoperative pancreatic s­tula: an international study group (ISGPF) denition. Surgery. 2005;138:8–13.
17. Strasberg SM, Bhalla S, Sanchez LA, Linehan DC. Pattern of venous collateral development after splenic vein occlusion in an extended Whipple procedure: comparison with collateral vein pat­tern in cases of sinistral portal hypertension. J Gastrointest Surg. 2011;15(11):2070–9.
18. Petrucciani N, Debs T, Rosso E, et al. Left-sided portal hyper­tension after pancreatoduodenectomy with resection of the por­tal/superior mesenteric vein conuence. Results of a systematic review. Surgery. 2020;168(3):434–9.
19. Gyoten K, Mizuno S, Nagata M, Ogura T, Usui M, Isaji S. Signicance of simultaneous splenic artery resection in left­sided portal hypertension after pancreaticoduodenectomy with combined portal vein resection. World J Surg. 2017;41(8):2111–20.
Pancreaticoduodenectomy withSuperior Mesenteric Resection andReconstruction forLocally Advanced Tumors
PhilippeBachellier andPietroAddeo
42
Abstract
Pancreatectomies with arterial resections were initially characterized by high postoperative mortality and poor long-term survival as reported by Fortner etal. and then abandoned. The introduction of new efcacious chemo­therapy regimens (FOLFIRINOX) along with the exten­sive experience in venous resection for borderline pancreatic tumors has brought renewed interest in extended pancreatic resection for locally advanced malig­nancy. The experience needed for performing such com­plex resections goes beyond pancreatic surgery alone and entails skills in vascular surgery. Reconstructing arterial vessels might need autologous and/or heterologous vas­cular substitutes which should be available immediately and accurate preoperative planning and simulation on the basis of cross-sectional imaging should be the rule. Resection of the superior mesenteric artery could be seen as one of the most challenging arterial resection at the time of pancreatectomy because of: (1) the frequent pres­ence of an associated venous invasion; (2) the variable degree of tumoral inltration downward through the mes­entery; (3) the necessity of a mesenteric approach and complete mesenteric dissection; (4) the need for recon­structing several jejunal and ileal branches; (5) the high mortality rates (20%) reported so far. In this chapter we will describe step-by-step the surgical technique of our standardized approach for superior mesenteric artery resection during pancreaticoduodenectomy.
P. Bachellier (*) · P. Addeo Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives, Hépatiques et de la Transplantation, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France e-mail: Philippe.Bachellier@chru-strasbourg.fr

42.1 Introduction

The introduction of new efcacious chemotherapy regimens (FOLFIRINOX) along with the extensive experience in venous resection for borderline pancreatic tumors has led to the development of extended pancreatic resection for locally advanced malignancy [14]. In these procedures the arterial vessels of the coeliac and superior mesenteric axes are resected and reconstructed simultaneously with pancreatec­tomy in order to achieve local control for locally advanced pancreatic malignancy. Pancreatectomies with arterial resec­tions were initially characterized by high postoperative mor­tality and poor long-term survival as reported by Fortner etal. and then abandoned [5, 6]. The establishment of high volume center for pancreatic resection along with experience in vascular resection during HPB surgery and liver and pan­creas transplant let some centers to revisit these procedures for patients with locally advanced disease [710]. The expe­rience needed for performing such complex resections goes beyond pancreatic surgery alone and entails skills in vascular surgery which can need a multidisciplinary approach includ­ing eventually vascular surgeons. Reconstructing arterial vessels might need autologous and/or heterologous vascular substitutes which should be available immediately. For these reasons accurate preoperative planning and simulation on the basis of cross-sectional imaging should be the rule when planning these procedures. The occurrence of pancreatic leak into the postoperative period could be very often a lethal event by causing erosion and thrombosis of reconstructed vessels and consequent death. These highlights such as arte­rial resections should be reserved to very high volume cen­ters to surgeons well beyond their learning curve with standard pancreatic resections [8]. Arterial resections are now gradually centralized in very high volume centers and as a matter of fact the largest series of arterial resection are now reported by few European, American and Asian centers [4,
1114]. Such as every surgical procedure some type of
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2022 M. Makuuchi et al. (eds.), The IASGO Textbook of Multi-Disciplinary Management of Hepato-Pancreato-Biliary Diseases,
https://doi.org/10.1007/978-981-19-0063-1_42
327